Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab CP2 vs CP4 in Postmenopausal Osteoporosis
NCT02157948Phase 3Completed
- Sponsor
- Amgen
- Start
- May 2014
- Primary completion
- Jul 2015
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial of denosumab in postmenopausal osteoporosis (2 arms), sponsored by Amgen. Primary endpoint: Percent Change From Baseline in Lumbar Spine Bone Mineral Density at 12 months. Started May 2014; status: completed.
02
Drugs
denosumab
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT02157948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02157948.